• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . A(H3N2) antigenic variation of influenza is associated with low vaccine efficacy in the early 2018 influenza season in Mexico Cit

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2022 Oct 22;S1201-9712(22)00567-7.
doi: 10.1016/j.ijid.2022.10.029. Online ahead of print.
A(H3N2) antigenic variation of influenza is associated with low vaccine efficacy in the early 2018 influenza season in Mexico City


Victor Alberto Hernández-Hernández[SUP] 1 [/SUP], Anjarath Lorena Higuera-Iglesias[SUP] 2 [/SUP], Gabriel Palma-Cortes[SUP] 3 [/SUP], Daniela Tapia-Trejo[SUP] 4 [/SUP], Santiago Ávila-Ríos[SUP] 4 [/SUP], Rubén Roberto González-Fernández[SUP] 3 [/SUP], Luis Ángel Pérez-Moreno[SUP] 3 [/SUP], Joaquín Alejandro Zuñiga-Ramos[SUP] 5 [/SUP], Cristóbal Guadarrama-Pérez[SUP] 6 [/SUP], José Luis Sandoval-Gutiérrez[SUP] 6 [/SUP], Carlos Cabello-Gutiérrez[SUP] 7 [/SUP]



Affiliations

Abstract

Background: The evolution of influenza viruses causes a decrease in vaccine effectiveness (VE), requiring constant monitoring of mutations and readjustments to the recommended composition of influenza vaccines. We evaluated the VE and the mutations of the viruses present in the Mexican population at the beginning of 2018.
Methods: We diagnosed influenza in outpatients with high-performance Rapid Influenza Diagnostic Test (RIDT) and qRT-PCR. Descriptive statistics were used to describe the study population, while a Xi[SUP]2[/SUP] was used to determine clinical variables. VE was analyzed through a negative test design. We sequenced the hemagglutinin (HA) gene, performed a phylogenetic analysis and analyzed the nonsynonymous substitutions both in- and outside antigenic sites.
Results: Of the 240 patients analyzed, 42.5% received the trivalent vaccine, and 37.5% were positive for influenza. The VE for the general population for any influenza virus type or subtype was 37.0%, while the VE for the predominant influenza A(H3N2) subtype was the lowest (19.7%). The phylogenetic analysis of HA showed the co-circulation of clades and subclades 3C.2a1, 3C.2a1b, 3C.2a2, 3C.2a2re, 3C.2a3, and 3C.3a with identities approximately 97%-98% similar to the vaccine composition.
Conclusions: The low VE was related to the co-circulation of multiple clades and subclades of influenza A(H3N2), with sufficient genetic and phenotypic distance to allow for the infection of vaccinated individuals.

Keywords: Influenza virus; and antigenic sites; clades; identity; outpatients; phylogeny; subclades.
 
Back
Top Bottom